echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > U.S. FDA approves Nuzyra (Omacycline) for oral administration only

    U.S. FDA approves Nuzyra (Omacycline) for oral administration only

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Zai Lab partner Paratek Pharmaceuticals recently announced that the U.
    S.
    Food and Drug Administration (FDA) has approved a supplementary new drug application (sNDA) for Nuzyra (omadacycline, omacycline tosylate, or "omacycline" for short).
    ): The oral-only dosing regimen of Nuzyra is used to treat adult patients with community-acquired bacterial pneumonia (CABP)
    .


    Previously, Nuzyra's administration regimen for CABP was an intravenous-oral regimen


    Recently, the FDA also approved Nuzyra's oral dosing regimen for the treatment of acute bacterial skin and skin tissue infections (ABSSSI) in adult patients
    .


    Previously, Nuzyra's dosing regimen for the treatment of ABSSI was also an intravenous-oral regimen


    Nuzyra was approved by the FDA in October 2018.
    The drug is a modern tetracycline antibiotic that is administered orally or intravenously once a day for the treatment of CABP and ABSSSI
    .


    The newly approved oral-only dosing regimen will enable doctors to treat patients in outpatient or primary care facilities, reducing or eliminating the risks and costs during hospitalization and hospitalization


    Omadacycline is a new type of 9-aminomethylcycline drug.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.